bacTRL CD3
Alternative Names: bacTRL-CD3Latest Information Update: 07 Dec 2020
At a glance
- Originator Symvivo
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 26 Oct 2020 bacTRL CD3 is available for licensing as of 26 Oct 2020. https://www.symvivo.com/contact
- 26 Oct 2020 Preclinical trials in Solid tumours in Canada (IV) before October 2020 (Symvivo pipeline, October 2020)